title: Family nutritional support improves survival, immune restoration and adherence in HIV patients receiving ART in developing country.
abstract: In developing countries, access to antiretroviral treatment for persons living with HIV is still in progress. Malnutrition represents another cause of acquired immunodeficiency and premature death. This evaluation program estimated the impact of family nutritional support during the first year of antiretroviral treatment in West Africa's sub-Sahara region. Family nutritional support was proposed to patients with CD-4 cell count <200 /mm3 and/or developing a WHO stage III/IV or with body mass index <18.5 kg/m2 and receiving antiretroviral treatment. Follow-up of 62 patients receiving support was compared to 118 patients who had only received antiretroviral treatment the year before. Average body mass index, CD-4 cell count were 20.7 and 20.5, 217 and 191/mm3 respectively in supported and control groups (NS). Twenty-two (36%) and 56 (48%) were WHO stage III/IV (NS) respectively in supported and control groups. One patient who received support and twelve controls died (Mortality Ratio=0.19; p<0.05). Increase in CD-4 cell count was around 1.7 times higher (+ 114 vs. + 68 CD-4 cells/mm3 respectively in supported and control groups; p<0.05) and observance was improved in supported group (p<0.005). The evolutions of WHO stage and body mass index were not different but the study period was short. Family nutritional support for persons living with HIV initiating antiretroviral treatment in a developing country showed a positive impact after six months. This family intervention could be integrated into AIDS interventions as an effective and comprehensive community-based primary care.
authors.affiliation: HIV/Hepatitis Department, Sainte Marguerite Hospital-APHM, Marseille, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Serrano
authors.forename: Remi
authors.initials: R
authors.lastname: Laporte
authors.forename: Moussa
authors.initials: M
authors.lastname: Ide
authors.forename: Yacouba
authors.initials: Y
authors.lastname: Nouhou
authors.forename: Pierre
authors.initials: P
authors.lastname: de Truchis
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Rouveix
authors.forename: Adiza
authors.initials: A
authors.lastname: Adamou
authors.forename: Vanessa
authors.initials: V
authors.lastname: Pauly
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Mattei
authors.forename: Jean-Albert
authors.initials: JA
authors.lastname: Gastaut
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D018791:CD4 Lymphocyte Count; D003631:Day Care, Medical / Q000458:organization & administration; D003906:Developing Countries / Q000706:statistics & numerical data*; D004032:Diet; D005190:Family; D005260:Female; D015658:HIV Infections / Q000178:diet therapy / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D006304:Health Status; D006801:Humans; D008297:Male; D009548:Niger; D009752:Nutritional Status; D012720:Severity of Illness Index; D016019:Survival Analysis; D016903:Drug Monitoring
chemical_list: D019380:Anti-HIV Agents